Cowen Thinks 3 Life Science Stocks Can Beat Earnings Estimates
In a new research report, Cowen analysts focus on three life science stocks that they think could beat current consensus earnings estimates.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 268Opposing Views on Gilead Hepatitis C Presentation
Gilead Sciences is a major biotech involved with the EASL conference, and two analysts are calling heads and tails in terms of what the HCV news means for the stock.
Can Perrigo Get More From Mylan?
Generic drug maker Mylan has proposed to acquire rival Perrigo for $205 per share in cash and stock.
What to Expect From Rite Aid Earnings
Rite Aid is scheduled to release its fiscal fourth-quarter financial results Wednesday morning before the markets open.
Dyax Shares Defy Gravity on Secondary Offering News
The newest hot stock in biotechnology is now giving everyone the chance to get a piece of it via an offering of 7 million shares of its common stock.
4 Big Pharmaceutical Stocks to Buy for the Rest of 2015
SunTrust Robinson Humphrey analysts expect the pharmaceutical industry to outperform in 2015, driven in part by a solid new product cycle and an attractive five-year growth rate.
Is a Big Share Buyback Coming to DaVita?
DaVita Healthcare Partners has a large amount of cash on its balance sheet and it does not pay a dividend. Should investors should expect a big stock buyback?
Catalysts and Data Could Move 4 Top Biotech Stocks to Buy
A new report from Stifel highlights four very solid biotech stocks that could bring home the bacon this year for investors and are not triple-digit priced.
4 Fresh Biotech Stock Picks With Targets 50% to 100% Higher
In the past week there were four analyst picks in and associated with the biotech area that came with gigantic upside price targets.
Is Nymox a Fluke or Is It Back?
Nymox Pharmaceutical shares rallied over 100% in the past week. Was that a fluke, or is Nymox really back in business?
Does the Mylan Secondary Make Its Stock Cheap?
Mylan has announced that it will have a 35 million share secondary offering. At Tuesday's closing price of $59.35, the offering would be valued at $2.08 billion.
Biotechs Raising New Capital in Droves
With the biotech industry so hot, it seems like many of the smaller players are trying to bolster their balance sheets to get enough capital for their future product pipeline plans.
Analysts Massively Increasing Dyax Price Targets
So far, analysts have not backed off their bullish views of Dyax. In fact, many analysts boosted their price targets remarkably on the news.
Why Dyax Will Dominate Biotech News on Wednesday
Dyax is almost certain to dominate the biotech news flow on Wednesday, after it announced positive trial data on Tuesday evening.
Ebola Finances Coming Back in the News
Within the past week, two Ebola-related companies are showing renewed optimism for their positions, whether it is securing a contract or raising capital.